GBD News

We have moved – as part of our expansion program for 2019-20 we have moved to new office space, increasing the size but still offering the same outstanding service. We can now be found at
SP5 1EZ.

Celebrating 30 Years in Business

August 2021 sees a major milestone for Greaves Best Design as we celebrate 30 years in business. Over 1,600 projects later we would like to take the opportunity to thank our clients who have been so supportive.

ai Rehab win Medilink Healthcare Business Award

July 2021 - ai Rehab have won a MedilinkHealthcare Business Award for Slider, a unique smart product based on augmented reality and wearable remote sensors.  Slider has been designed to motivate patients to do pre and postop hip and knee exercises and to measure complianceand progress. We incorporate alerts for remote notification when the patient’s progress deviates from the pathway and PROMS to standardize outcome measures and measurable results physiotherapy.

Latest M-KOPA Solar 'Solar Home System' launched

The MK6000 has just launched for M-KOPA Solar. The larger, more powerful control unit can power either a 32'' TV and accessories set (2 lamps, 2 strip lights, radio and torch) or a 100 litre fridge and lighting.

100,000th subscriber in Uganda for M-KOPA

Haddijah Nakintu, a business woman form Mpelerwe is the 100,000th subscriber in Uganda meaning that there are now over 630,000 homes connected to M-KOPA across Africa. Haddijah says, ''M-KOPA is a great invention. It will address the unreliable power supply in my area, help me save power money and even earn more money in the shop. Showing the TV will bring in more customers and my family can also relax here with me when we're open late.''

Clinical Trial for HeadsUp

Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, has commenced a clinical trial to evaluate it's urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five urinary biomarkers associated with the onset of pulmonary exacerbation in adults with CF. It will also validate the use of the novel point-of-care (POC) test for patient's self monitoring of their condition.